Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Guardant Health, Inc. (GH)
Price$161.41Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $982.0M | $739.0M | $563.9M | $449.5M | $373.7M | $286.7M | $214.4M | $90.6M | $49.8M |
| Gross profit | $633.0M | $449.2M | $336.9M | $293.2M | — | — | — | — | — |
| Gross margin | 64.46% | 60.79% | 59.74% | 65.23% | — | — | — | — | — |
| Research & development | $364.2M | $347.8M | $367.2M | $373.8M | $263.2M | $149.9M | $86.3M | $50.7M | $25.6M |
| Operating expenses | $1.42B | $1.18B | $1.13B | $993.9M | $784.7M | $541.7M | $296.7M | $183.6M | $126.5M |
| Operating income | −$437.2M | −$443.6M | −$564.7M | −$544.4M | −$411.0M | −$254.9M | −$82.4M | −$92.9M | −$76.6M |
| Operating margin | −44.53% | −60.02% | −100.14% | −121.10% | −110.00% | −88.92% | −38.42% | −102.54% | −153.71% |
| EBITDA | −$397.5M | −$401.2M | −$521.8M | −$508.4M | −$388.7M | −$238.9M | −$71.0M | −$85.8M | −$71.4M |
| EBITDA margin | −40.48% | −54.29% | −92.53% | −113.10% | −104.04% | −83.31% | −33.10% | −94.67% | −143.26% |
| Net income | −$416.3M | −$436.4M | −$479.4M | −$654.6M | −$384.8M | −$246.3M | −$75.7M | −$85.1M | −$83.2M |
| Net profit margin | −42.39% | −59.05% | −85.02% | −145.61% | −102.98% | −85.89% | −35.29% | −93.85% | −166.97% |
| Basic EPSper basic share | -$3.32 | -$3.56 | -$4.28 | -$6.41 | -$4.00 | -$2.60 | -$0.84 | -$2.80 | -$7.07 |
| Diluted EPSper diluted share | -$3.32 | -$3.56 | -$4.28 | -$6.41 | -$4.00 | -$2.60 | -$0.84 | -$2.80 | -$7.07 |
Owners
Reported shareholders
5.71%of listed shares
BlackRock, Inc.7.62M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 5.71%7.62M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 4.88%6.51M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.31%5.76M shares |
FMR LLC | 4.11%5.49M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.08%5.45M shares |
Invesco Ltd. | 3.32%4.43M shares |
GOLDMAN SACHS GROUP INC | 2.83%3.78M shares |
TWO SIGMA INVESTMENTS, LP | 2.78%3.72M shares |
Capital International Investors | 2.54%3.4M shares |
Deep Track Capital, LP | 2.54%3.39M shares |
FRANKLIN RESOURCES INC | 2.42%3.24M shares |
AMERIPRISE FINANCIAL INC | 2.36%3.15M shares |
FULLER & THALER ASSET MANAGEMENT, INC. | 1.97%2.63M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.89%2.52M shares |
BAILLIE GIFFORD & CO | 1.71%2.28M shares |
STATE STREET CORP | 1.69%2.26M shares |
Eltoukhy Helmy | ≈1.51%2.01M shares |
FEDERATED HERMES, INC. | 1.50%2M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 1.47%1.96M shares |
Talasaz AmirAli | ≈1.41%1.88M shares |
Percentages use 133.61M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Talasaz AmirAliCo-Chief Executive Officer | SellCommon Stock · indirect | 40 | $153.00 | $6.1K | 1.88M |
| Jun 29, 2026Form 4 · 10b5-1 | Talasaz AmirAliCo-Chief Executive Officer | SellCommon Stock · indirect | 46.7K | $152.20 | $7.10M | 1.88M |
| Jun 29, 2026Form 4 · 10b5-1 | Talasaz AmirAliCo-Chief Executive Officer | SellCommon Stock · indirect | 70.5K | $151.47 | $10.68M | 1.93M |
| Jun 29, 2026Form 4 · 10b5-1 | Talasaz AmirAliCo-Chief Executive Officer | SellCommon Stock · indirect | 25.8K | $150.53 | $3.89M | 2.00M |
| Jun 26, 2026Form 4 · 10b5-1 | Talasaz AmirAliCo-Chief Executive Officer | SellCommon Stock · indirect | 52.9K | $151.16 | $8.00M | 1.88M |